Escherichia coli TUH12191, which is resistant to piperacillin, cefazolin, cefotiam, ceftizoxime, cefuzonam, and aztreonam but is susceptible to cefoxitin, latamoxef, flomoxef, and imipenem, was isolated from the urine of a patient treated with ␤-lactam antibiotics. The ␤-lactamase (Toho-1) purified from the bacteria had a pI of 7.8, had a molecular weight of about 29,000, and hydrolyzed ␤-lactam antibiotics such as penicillin G, ampicillin, oxacillin, carbenicillin, piperacillin, cephalothin, cephaloridine, cefoxitin, cefotaxime, ceftazidime, and aztreonam. Toho-1 was markedly inhibited by ␤-lactamase inhibitors such as clavulanic acid and tazobactam. Resistance to ␤-lactams, streptomycin, spectinomycin, sulfamethoxazole, and trimethoprim was transferred by conjugational transfer from E. coli TUH12191 to E. coli ML4903, and the transferred plasmid was about 58 kbp, belonging to incompatibility group M. The cefotaxime resistance gene for Toho-1 was subcloned from the 58-kbp plasmid by transformation of E. coli MV1184. KTG). Toho-1 was about 83% homologous to the ␤-lactamase mediated by the chromosome of K. oxytoca D488 and the ␤-lactamase mediated by the plasmid of E. coli MEN-1. Therefore, the newly isolated ␤-lactamase Toho-1 produced by E. coli TUH12191 is similar to ␤-lactamases produced by K. oxytoca D488, K. oxytoca E23004, and E. coli MEN-1 rather than to mutants of TEM or SHV enzymes. Toho-1 has shown the highest degree of similarity to K. oxytoca class A ␤-lactamase. Detailed comparison of Toho-1 with other ␤-lactamases implied that replacement of Asn-276 by Arg with the concomitant substitution of Thr for Arg-244 is an important mutation in the extension of the substrate specificity.Expanded-spectrum cephalosporins have chemical structures which confer stability to many ␤-lactamases from gram-negative bacteria. However, many members of the family Enterobacteriaceae other than Escherichia coli developed resistance to the expanded-spectrum cephems (40). The primary mechanism of this resistance was demonstrated to be excessive production of a chromosomal ␤-lactamase (AmpC) (23). However, bacteria that show resistance mediated by other ␤-lactamases appeared in 1984 (8). Species of the Enterobacteriaceae such as Klebsiella pneumoniae, Klebsiella oxytoca, and E. coli acquired resistance against expanded-spectrum cephem antibiotics by producing extended-spectrum ␤-lactamase. The extended spectrum of the ␤-lactamase was often acquired by the variation of ␤-lactamase genes on transmissible plasmids (43,44). Under the influence of antimicrobial agents, bacteria producing primarily TEM-type or SHV-type ␤-lactamases developed point mutations in structural genes which served to extend the substrate specificity of the enzymes (44). These TEM-type and SHV-type ␤-lactamases show about 65% amino acid sequence homology, with isoelectric points of 5.5 to 6.3 and 7.0 to 8.2, respectively (8, 9).

Protein tyrosine phosphatase receptor-type Z (PTPRZ) is aberrantly over-expressed in glioblastoma and a causative factor for its malignancy. However, small molecules that selectively inhibit the catalytic activity of PTPRZ have not been discovered. We herein performed an in vitro screening of a chemical library, and identified SCB4380 as the first potent inhibitor for PTPRZ. The stoichiometric binding of SCB4380 to the catalytic pocket was demonstrated by biochemical and mass spectrometric analyses. We determined the crystal structure of the catalytic domain of PTPRZ, and the structural basis of the binding of SCB4380 elucidated by a molecular docking method was validated by site-directed mutagenesis studies. The intracellular delivery of SCB4380 by liposome carriers inhibited PTPRZ activity in C6 glioblastoma cells, and thereby suppressed their migration and proliferation in vitro and tumor growth in a rat allograft model. Therefore, selective inhibition of PTPRZ represents a promising approach for glioma therapy.

Comparison of the hydrogen-bond networks at the active site in the crystallographic structures reported for class A beta-lactamases revealed an importance of a switch of the hydrogen-bond network for the catalytic process. Taking account of the conformational mobility of the Lys73 residue, we have constructed putative complex models for beta-lactam antibiotics and the enzymes in the multistep hydrolysis which consists of a Michaelis complex, an acyl-enzyme, and a tetrahedral oxyanion for deacylation. In the acylation, the C3 carboxylate of penicillin derivatives would participate in activation of the Ser130 hydroxyl group and then the oxyanion of the Ser130 residue would deprotonate the ammonium group of the Lys73 residue which will act as a general base for activation of the Ser70 residue. In the deacylation, the deacylating water molecule would be accommodated during a conformational change of the acyl moiety without a structural change of the active-site residues and the unprotonated N4 atom of the penicillins would act as a general base to activate the water molecule. This catalytic process provided a new account for the stability of the acyl-enzyme complexes. This substrate-assisted mechanism would also be extended to a hydrolytic mechanism of class C enzymes.

No abstract

No abstract